SUMMARY The renal kallikrein-kinin system, distinct from the plasma system, is an enzyme sequence producing kinins, principally lysyl bradykinin. While the functions of the system have not been conclusively established, it has been implicated in renal vasodilation and natriuresis, although the evidence is often conflicting. Measurement of urinary kallikrein excretion is the most common way to assess the system, although kallikrein excretion and kinin excretion are often dissociated. Kallikrein excretion is influenced by several hormonal systems, as well as dietary alterations, disease states (including hypertension), and numerous drugs. Kallikrein excretion is diminished in hypertension (especially hypertension with reduced renal function), suggesting involvement in the pathogenesis of the disease. Dietary sodium restriction increases kallikrein excretion while lowering blood pressure, but the blood pressure reduction correlates with plasma volume contraction rather than the increase in kallikrein. Thiazide diuretics lower blood pressure and renal vascular resistance while increasing kallikrein excretion, and blood pressure "responders" to thiazides have a greater kallikrein increment than the "nonresponders," suggesting a role for renal kallikrein in the hypotensive response to thiazides. T HE kallikrein-kinin system in the kidney is an enzymatic system generating certain yasoactive peptides called kinins ( fig. 1 ). This review discusses the renal kallikrein-kinin system; its relation to the plasma kallikrein-kinin system; its components, measurement, putative actions; influences upon its activity; abnormalities of the system in human hypertension; and response of the renal kallikreinkinin system, along with renal hemodynamics and intravascular volume, to dietary and drug manipulations of sodium balance in the treatment of essential hypertension.
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The Renal and Plasma Kallikrein-Kinin Systems Several tissues, including kidney, pancreas, and salivary glands 1 " 7 possess kallikrein-kinin systems. The tissue or "glandular" kallikrein-kinin systems, while similar to each other, differ from the plasma kalli-KALLIKREIN AFTER SALT RESTRICTION AND DIURETICS/0 1 Connor 111-73 similar to, if not identical to, those of renal kallikrein." There may also be a proteolytically activated prekallikrein in urine. 2 Urinary kallikrein acts upon its kininogen substrate, 24 ' l2 cleaving off principally the decapeptide lysyl bradykinin (kallidin), which may in turn be converted to bradykinin by an aminopeptidase ( fig.  1) . Kidney kallikrein and kininogen may meet not only in urine but also in kidney interstitium, 13 perhaps along the basolateral tubular membrane;
14 thus, active kinins may be produced not only in the urine, but also in the kidney parenchyma. Kininases I and II (kininase II is also the angiotensin-converting enzyme) 15 catabolize the kinins to inert peptides.
15 -l6
The renal kallikrein-kinin system is usually assessed by measurement of kallikrein activity in timed urine collections, typically 24 hours, though studies assessing multiple components of the system have been recommended.
1 " 5 Urinary kallikrein is also an esterase at alkaline pH; hence, urinary alkaline esterase activity provides an index of kallikrein excretion, 17 though kallikrein can also be quantitated by kininogenase activity, 4 direct radioimmunoassay,' 8 ' " or radial immunodiffusion. 20 While some studies have suggested a dissociation between urinary alkaline esterase activity and true kallikrein, 1 ' 20 recent reports indicate that alkaline esterase activity correlates well (r > 0.9) with both kininogenase activity and kallikrein by direct radioimmunoassay.
While several putative actions of the renal kallikrein-kinin system have been studied, none has been definitively established (table 1) . Kallikrein excretion correlates with renal blood flow in both normotensive and hypertensive humans, 21 suggesting a vasodilatory kallikrein-kinin action on the renal circulation, though, on the other hand, kallikrein changes may be secondary to the renal blood flow changes. 35 and directly with water loading and excretion, 36 although this remains controversial. 26 Drug influences upon kallikrein excretion mandate careful control of drug intake, as well as diet composition, during studies of kallikrein excretion. 
Urinary Kallikrein Excretion in Human Hypertension
Urinary kallikrein excretion is diminished in essential hypertension, 21262737 though cause and effect have not been elucidated. There is much overlap between hypertensives and normotensives; 37 -38 and there is no definite, consistent relationship between renal kallikrein and either plasma or urinary kinin generation. 40 -41 Figure 3 illustrates the influences of essential hypertension, race, and dietary sodium intake upon kallikrein excretion: 21 whites excrete more kallikrein than blacks, and white hypertensives excrete less kallikrein than white normotensives. All groups have greater kallikrein excretion on low sodium intake, with a blunted increment in black hypertensives on low salt intake. Black hypertensives excrete less kallikrein than black normotensives only during sodium restriction.
Kallikrein excretion is also abnormal in several varieties of secondary hypertension (table 2) : it is elevated in mineralocorticoid hypertension, 27 -37 and depressed in renal parenchymal hypertension, 42 hypertension after renal transplant, 43 and diabetic hypertension. 44 Kallikrein excretion may change during antihyperterisive therapy ( To explore the antihypertensive response to sodium restriction, we assessed the response of blood pressure, renal hemodynamics, intravascular volume, and kallikrein excretion to short term, moderately severe sodium restriction in 38 mild to moderate essential hypertensives. 47 After 5 days on a high salt diet (177 ± 17 mEq sodium excreted/day) and again after 5 days on a low salt diet (35 ± 12 mEq sodium excreted/day), Fall in blood pressure correlated well with plasma volume contraction (r = -0 . 6 7 , p < 0.01, n = 23; fig.  4 ), though not with change in weight (r = 0.30, p > 0.1), suggesting that the important volume decrement for blood pressure reduction was that one-eighth derived from plasma volume contraction. There was a modest deterioration in renal perfusion, with declines in glomerular filtration rate, renal plasma flow, and renal blood flow, and a rise in renal vascular resistance. Both plasma renin activity and urinary kallikrein excretion increased on low salt diet (table 4), though the kallikrein increment did not correlate with blood pressure decrement (r = 0.12, p > 0.1), suggesting that the renal kallikrein-kinin system is not involved in the antihypertensive effect of salt restriction.
Diuretic Treatment
To explore the antihypertensive response to thiazide diuretics, we also assessed the response of blood pressure, renal hemodynamics, intravascular volume, and kallikrein excretion to long-term thiazide monotherapy in 19 mild to moderate essential hypertensives on unrestricted fluid and salt intake. 45 After 1 month on placebo, and again after 1 month on hydrochlorothia-A PLASMA VOLUME, ml zide monotherapy (range 25-100 mg/day, median 50 mg/day), we measured blood pressure, weight, renal hemodynamics, intravascular volume, plasma renin activity, plasma aldosterone concentration, and urinary kallikrein activity.
Blood pressure fell (table 5) 43 , p > 0.1) plasma aldosterone concentration, although we did not measure aldosterone secretory rates and cannot exclude the possibility that endogenous mineralocorticoid influenced the kallikrein results. However, patients with a greater blood pressure response O 10% reduction, n = 12) to thiazides had a greater kallikrein increment ( fig. 6 ) than those without a blood pressure fall ( < 10% reduction, n = 7), suggesting a role for the renal kallikrein-kinin system and renal hemodynamics in the antihypertensive response to thiazide diuretics. However, we have not established a cause and effect relation between the increase in kallikrein and the decline in blood pressure and renal vascular resistance.
Conclusions
The deficit in kallikrein excretion seen in hypertension may be restored during successful antihypertensive therapeutic manipulation of sodium balance, both by dietary sodium restriction and by thiazide diuretic treatment. Whether the increase in kallikrein excretion is simply a function of the blood pressure fall and hormonal changes, or is instead a mediator of the blood pressure fall, remains to be established. 
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